RINVOQ disrupts the unrelenting itch and rash of atopic dermatitis across a range of patient types.1
Select a patient below to see how RINVOQ can help patients like yours.
DARIUS
Inadequately controlled on multiple rounds of oral corticosteroids
CLINICAL PROFILE
- Age 34 years
- BSA score 45%
- EASI score 29
- vIGA score 4
- Worst pruritus NRS score
(weekly average) 7
MEDICAL HISTORY
Controlled hypertension
Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with RINVOQ, particularly in patients with other CV factors. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.
Clinical Presentation
- Increased frequency of scratching
- Residual itch and flaky skin
Treatment Goals
- Prefers oral treatment
- Fast itch relief
- Clearer skin
RAPID RELIEF
EASI 75 and vIGA 0/1 measured at Week 16, with EASI 75 rates seen as early as Week 21,3
Reduced worst pruritus NRS ≥4 measured at Week 16, rates observed within 2 days after first dose3-5
RYAN
Inadequately controlled on systemic therapies
CLINICAL PROFILE
- Age 14 years
- BSA score 15%
- EASI score 25
- vIGA score 3
- Worst pruritus NRS score
(weekly average) 6
MEDICAL HISTORY
None
Clinical Presentation
- Persistent itch, scaly red rashes,
and lesions - Feels the need to cover up skin in
front of a crowd
Treatment Goals
- Itch relief
- Prefers an oral pill
- Wants clearer skin
DURABLE CONTROL
Co-primary endpoints EASI 75 and vIGA 0/1 controlled at Week 161
Response rates observed up to 52 Weeks4
ASHLEY
Inadequately controlled on systemic therapies
CLINICAL PROFILE
- Age 40 years
- BSA score 20%
- EASI score 30
- vIGA score 4
- Worst pruritus NRS score
(weekly average) 7
MEDICAL HISTORY
Currently on oral contraceptives
Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with RINVOQ, particularly in patients with other CV factors. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.
Uncontrolled on oral steroidsThis is not a real patient. Image reflects a patient on RINVOQ after 16 weeks of treatment.
I was hoping for something that would provide fast relief from my eczema symptoms. RINVOQ provided rapid relief from the itch and rash
DARIUS
Inadequately controlled on multiple rounds of oral corticosteroids
CLINICAL PROFILE
- Age 34 years
- BSA score 45%
- EASI score 29
- vIGA score 4
- Worst pruritus NRS score
(weekly average) 7
MEDICAL HISTORY
Controlled hypertension
Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with RINVOQ, particularly in patients with other CV factors. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.
Clinical Presentation
- Increased frequency of scratching
- Residual itch and flaky skin
Treatment Goals
- Prefers oral treatment
- Fast itch relief
- Clearer skin
RAPID RELIEF
EASI 75 and vIGA 0/1 measured at Week 16, with EASI 75 rates seen as early as Week 21,3
Reduced worst pruritus NRS ≥4 measured at Week 16, rates observed within 2 days after first dose3-5
Age 12+ and uncontrolled on systemic therapyThis is not a real patient. Image reflects a patient on RINVOQ after 16 weeks of treatment.
Because my skin is clearer and I have less itch, I finally feel comfortable in my own skin
RYAN
Inadequately controlled
on systemic therapies
CLINICAL PROFILE
- Age 14 years
- BSA score 15%
- EASI score 25
- vIGA score 3
- Worst pruritus NRS score
(weekly average) 6
MEDICAL HISTORY
None
Clinical Presentation
- Persistent itch, scaly red rashes,
and lesions - Feels the need to cover up skin in
front of a crowd
Treatment Goals
- Itch relief
- Prefers an oral pill
- Wants clearer skin
DURABLE CONTROL
Co-primary endpoints EASI 75 and vIGA 0/1 controlled at Week 161
Response rates observed up to 52 Weeks4
Uncontrolled on systemic therapyThis is not a real patient. Image reflects a patient on RINVOQ after 16 weeks of treatment.
When I tried RINVOQ, it helped with my itch and rash symptoms
ASHLEY
Inadequately controlled
on systemic therapies
CLINICAL PROFILE
- Age 40 years
- BSA score 20%
- EASI score 30
- vIGA score 4
- Worst pruritus NRS score
(weekly average) 7
MEDICAL HISTORY
Currently on oral contraceptives
Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with RINVOQ, particularly in patients with other CV factors. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.
Clinical Presentation
- Itchy rash on trunk of the body
- Unable to achieve clearer skin
Treatment Goals
- Skin clearance on visible areas
- Wants one therapy, once a day